ABT
Abbott Laboratories NYSE Listed Mar 17, 1980$88.38
-0.14%
vs $88.50
Mkt Cap $153.9B
52w Low $81.97
11.2% of range
52w High $139.06
50d MA $90.43
200d MA $113.85
P/E (TTM)
23.8x
EV/EBITDA
13.5x
P/B
2.9x
Debt/Equity
0.3x
ROE
12.1%
P/FCF
20.9x
RSI (14)
58.20
ATR (14)
$2.06
Beta
0.78
50d MA
$90.43
200d MA
$113.85
Avg Volume
13.3M
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
100 Abbott Park Road · Abbott Park, IL 60064-6400 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | AMC | 1.14 | 1.15 | +0.9% | 95.47 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% | — |
| Jan 22, 2026 | AMC | 1.50 | 1.50 | +0.0% | 108.61 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% | — |
| Oct 15, 2025 | AMC | 1.30 | 1.30 | +0.0% | 129.45 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% | — |
| Jul 17, 2025 | AMC | 1.26 | 1.26 | +0.0% | 120.51 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% | — |
| Apr 16, 2025 | AMC | 1.07 | 1.09 | +1.9% | 129.70 | +0.5% | +1.0% | -0.8% | +1.4% | -1.4% | -0.4% | — |
| Jan 22, 2025 | AMC | 1.34 | 1.34 | +0.0% | 117.78 | +0.3% | +4.6% | +1.5% | +3.5% | -1.6% | +0.4% | — |
| Oct 16, 2024 | AMC | 1.20 | 1.21 | +0.8% | 117.82 | +0.8% | +0.1% | +1.3% | -2.0% | -0.7% | +0.8% | — |
| Jul 18, 2024 | AMC | 1.10 | 1.14 | +3.6% | 100.07 | +0.5% | +2.0% | +1.7% | +0.2% | +3.2% | -1.2% | — |
| Apr 17, 2024 | AMC | 0.95 | 0.98 | +2.6% | 105.90 | +0.6% | -0.6% | +1.9% | -0.2% | +0.5% | -0.7% | — |
| Jan 24, 2024 | AMC | 1.19 | 1.19 | +0.0% | 110.77 | +0.6% | +1.5% | -0.4% | +1.3% | +0.0% | -0.3% | — |
| Oct 18, 2023 | AMC | 1.10 | 1.14 | +3.6% | 95.56 | +1.0% | -0.1% | +1.4% | -1.0% | -1.0% | -1.3% | — |
| Jul 20, 2023 | AMC | 1.04 | 1.08 | +3.8% | 111.83 | +0.9% | +2.2% | +0.3% | -1.5% | +1.0% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $91.13 | $91.62 | +0.5% | +1.8% | +1.1% | -2.7% | -0.6% | -1.5% |
| Apr 22 | Daiwa Securities | Downgrade | Outperform → Neutral | $92 | $92.72 | $92.62 | -0.1% | -1.1% | +0.9% | -1.5% | +1.8% | +1.1% |
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $96.81 | $96.50 | -0.3% | -0.8% | -3.4% | -1.1% | +0.9% | -1.5% |
| Apr 17 | BofA Securities | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Benchmark | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | BTIG | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 17 | Stifel | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | -0.8% | -3.4% | -1.1% | +0.9% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $103.56 | $103.00 | -0.5% | -0.8% | -2.4% | +0.4% | +0.4% | +0.5% |
| Apr 8 | Barclays | Maintains | Overweight → Overweight | — | $101.83 | $103.13 | +1.3% | +1.7% | -0.8% | -2.4% | +0.4% | +0.4% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $102.87 | $102.51 | -0.3% | -0.6% | -0.5% | +1.7% | -0.8% | -2.4% |
| Mar 31 | BTIG | Maintains | Buy → Buy | — | $101.88 | $102.54 | +0.6% | +0.8% | -0.3% | +0.5% | -0.6% | -0.5% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $104.83 | $104.39 | -0.4% | -0.2% | -0.6% | -2.0% | +0.8% | -0.3% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $110.55 | $110.00 | -0.5% | -0.3% | -1.9% | -0.1% | +1.8% | +0.7% |
| Feb 2 | Barclays | Maintains | Overweight → Overweight | — | $109.30 | $109.23 | -0.1% | +0.1% | -0.4% | -0.8% | +0.8% | +1.6% |
| Jan 29 | Freedom Broker | Upgrade | Hold → Buy | — | $106.05 | $106.44 | +0.4% | +0.0% | +3.0% | +0.1% | -0.4% | -0.8% |
| Jan 23 | BTIG | Maintains | Buy → Buy | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Evercore ISI | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Citigroup | Maintains | Buy → Buy | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Bernstein | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $108.61 | $108.27 | -0.3% | -1.1% | +1.3% | -0.5% | -2.1% | +0.0% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $126.18 | $126.42 | +0.2% | -0.2% | -1.0% | -0.3% | +0.6% | -1.2% |
| Jan 5 | Barclays | Maintains | Overweight → Overweight | — | $124.19 | $123.63 | -0.5% | +1.8% | +1.1% | -0.6% | -0.7% | -0.2% |
| Nov 20 | BTIG | Maintains | Buy → Buy | — | $126.15 | $122.50 | -2.9% | -1.7% | +3.3% | -0.7% | +0.7% | +0.4% |
| Oct 17 | Barclays | Maintains | Overweight → Overweight | — | $127.63 | $127.86 | +0.2% | +0.7% | +0.8% | -1.5% | +0.3% | -1.3% |
| Oct 16 | RBC Capital | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | Raymond James | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 16 | Evercore ISI | Maintains | Outperform → Outperform | — | $129.45 | $129.53 | +0.1% | -1.4% | +0.7% | +0.8% | -1.5% | +0.3% |
| Oct 15 | BTIG | Maintains | Buy → Buy | — | $133.27 | $128.01 | -3.9% | -2.9% | -1.4% | +0.7% | +0.8% | -1.5% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $133.74 | $134.09 | +0.3% | -0.5% | +0.9% | -0.7% | -0.6% | -0.9% |
| Sep 10 | Bernstein | Maintains | Outperform → Outperform | — | $131.95 | $131.85 | -0.1% | -2.0% | +2.5% | +0.8% | -1.8% | +1.1% |
| Jul 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Citigroup | Maintains | Buy → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Raymond James | Maintains | Outperform → Outperform | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Jefferies | Upgrade | Hold → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | BTIG | Maintains | Buy → Buy | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 18 | Mizuho | Maintains | Neutral → Neutral | — | $120.51 | $122.63 | +1.8% | +2.6% | +0.6% | +1.1% | +0.1% | -0.2% |
| Jul 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $131.74 | $126.55 | -3.9% | -8.5% | +2.6% | +0.6% | +1.1% | +0.1% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $131.49 | $132.12 | +0.5% | +0.2% | -8.5% | +2.6% | +0.6% | +1.1% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $132.03 | $131.90 | -0.1% | -0.4% | +0.2% | -8.5% | +2.6% | +0.6% |
| Jul 15 | RBC Capital | Maintains | Outperform → Outperform | — | $132.03 | $131.90 | -0.1% | -0.4% | +0.2% | -8.5% | +2.6% | +0.6% |
| Jul 14 | BTIG | Maintains | Buy → Buy | — | $132.02 | $132.02 | +0.0% | +0.0% | -0.4% | +0.2% | -8.5% | +2.6% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $133.36 | $133.47 | +0.1% | -0.1% | +0.3% | -1.2% | +0.0% | -0.4% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $133.70 | $133.24 | -0.3% | -0.3% | -0.1% | +0.3% | -1.2% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Stratton John G | — | Buy | 2,000 | $86.82 | $174K | 23,319 | — | — |
| Apr 27, 2026 | STARKS DANIEL J | — | Buy | 10,000 | $92.65 | $927K | 6,751,103 | -2.70% | -0.15% |
| Apr 23, 2026 | Boudreau Philip P | EVP AND CFO | Buy | 2,200 | $91.50 | $201K | 2,200 | +1.14% | -2.15% |
8-K · 5.02
!!! Very High
Abbott Laboratories -- 8-K 5.02: Executive Change
Apr 27
8-K · 8.01
!! High
Abbott Laboratories -- 8-K 8.01: Material Event / Announcement
Abbott settled six shareholder derivative lawsuits related to its infant formula crisis for an undisclosed amount, with the settlement requiring court approval and potentially affecting director and officer liability exposure.
Apr 17
8-K
Unknown — 8-K Filing
Abbott is reminding investors that management relies on non-GAAP metrics internally, but GAAP results should remain primary—suggesting actual reported earnings may look weaker than management's preferred performance measures.
Apr 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive effective April 15, 2026 signals potential leadership uncertainty; investors should monitor whether the replacement demonstrates strategic continuity or signals broader organizational concerns affecting these companies' performance.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott's failure to promote Teplitsky to COO signals internal management instability and potential leadership challenges, which could concern investors about strategic direction and executive bench strength.
Apr 9
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Abbott has completed a significant acquisition, likely expanding its product portfolio and market reach, which could drive revenue growth and shareholder value if the target company's assets integrate successfully.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Abbott Laboratories announced a significant transaction with Exact Sciences Corporation on March 23, 2026, potentially indicating a major acquisition or partnership that could reshape its diagnostic business and impact future growth prospects.
Mar 23
8-K
Unknown — 8-K Filing
Abbott's acquisition of Exact Sciences faces material business risks that could impact integration success and profitability, warranting investor scrutiny of synergy realization and operational challenges ahead.
Mar 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K · 1.01
! Medium
Abbott Laboratories -- 8-K 1.01: Financing / Debt Agreement
Abbott Laboratories issued debt notes through underwriters Morgan Stanley, Barclays, and BofA Securities, expanding its financing capacity for future operations and strategic investments.
Mar 9
8-K · 1.01
!! High
Abbott Laboratories -- 8-K 1.01: Material Agreement
Abbott Laboratories entered into a pricing agreement with Morgan Stanley, Barclays Capital, and BofA Securities, likely for a debt or equity offering, establishing standard contractual protections for the underwriting transaction.
Feb 26
8-K
EXACT SCIENCES CORP -- 8-K Filing
Exact Sciences shareholders approved the company's acquisition by Abbott Laboratories, clearing the final regulatory and shareholder hurdle for the deal to close.
Feb 20
8-K · 5.03
! Medium
Abbott Laboratories -- 8-K 5.03: Amendment to Articles / Bylaws
Abbott Laboratories changed its fiscal year-end, which may affect future earnings report timing and investor planning for financial statement releases.
Feb 20
8-K
EXACT SCIENCES CORP -- 8-K Filing
Abbott faces lawsuit allegations of violating New York and Wisconsin securities laws in connection with its acquisition of Exact Sciences, potentially creating legal and financial risks for both companies.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 112,949,933 | $11.6B | New | Mar 2026 |
| 2 | Morgan Stanley | 73,455,066 | $9.2B | Reduced | Dec 2025 |
| 3 | Capital Research Global Investors | 49,775,362 | $5.1B | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 47,944,891 | $4.9B | New | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 26,767,099 | $2.7B | Added | Mar 2026 |
| 6 | Franklin Resources Inc | 20,022,905 | $2.1B | Added | Mar 2026 |
| 7 | Northern Trust Corp | 19,394,974 | $2.0B | Reduced | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 19,279,608 | $2.0B | Reduced | Mar 2026 |
| 9 | Wells Fargo & Company/mn | 15,909,341 | $1.6B | New | Mar 2026 |
| 10 | State Farm Mutual Automobile Insurance Co | 13,587,118 | $1.4B | — | Mar 2026 |
| 11 | Bank Of New York Mellon Corp | 12,442,717 | $1.3B | Reduced | Mar 2026 |
| 12 | Ubs Group Ag | 12,152,765 | $1.2B | Added | Mar 2026 |
| 13 | Nuveen, Llc | 11,191,853 | $1.1B | Reduced | Mar 2026 |
| 14 | Fmr Llc | 10,845,315 | $1.1B | Added | Mar 2026 |
| 15 | Invesco Ltd. | 9,853,603 | $1.0B | Reduced | Mar 2026 |
| 16 | Grantham, Mayo, Van Otterloo & Co. Llc | 8,910,945 | $915M | Added | Mar 2026 |
| 17 | Janus Henderson Group Plc | 8,092,917 | $831M | New | Mar 2026 |
| 18 | Flossbach Von Storch Se | 7,858,443 | $807M | Added | Mar 2026 |
| 19 | Amundi | 7,406,961 | $760M | New | Mar 2026 |
| 20 | Royal Bank Of Canada | 6,463,522 | $664M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity 500 Index Fund | 22,129,318 | $2.6B | Feb 2026 |
| 2 | iShares Core S&P 500 ETF | 22,364,057 | $2.3B | Mar 2026 |
| 3 | Washington Mutual Investors Fund | 16,068,099 | $1.8B | Jan 2026 |
| 4 | Capital Income Builder | 9,628,283 | $1.1B | Jan 2026 |
| 5 | VANGUARD DIVIDEND APPRECIATION INDEX FUND | 9,549,677 | $1.0B | Jan 2026 |
| 6 | VANGUARD HEALTH CARE FUND | 9,253,894 | $1.0B | Jan 2026 |
| 7 | JPMorgan Large Cap Growth Fund | 8,678,880 | $891M | Mar 2026 |
| 8 | MFS Value Fund | 7,174,314 | $835M | Feb 2026 |
| 9 | VANGUARD WELLINGTON FUND | 6,955,478 | $809M | Feb 2026 |
| 10 | VANGUARD HIGH DIVIDEND YIELD INDEX FUND | 6,968,053 | $762M | Jan 2026 |
| 11 | Capital World Growth & Income Fund | 6,139,710 | $714M | Feb 2026 |
| 12 | VANGUARD DIVIDEND GROWTH FUND | 5,295,066 | $579M | Jan 2026 |
| 13 | iShares U.S. Medical Devices ETF | 5,248,394 | $539M | Mar 2026 |
| 14 | Columbia Dividend Income Fund | 4,407,481 | $513M | Feb 2026 |
| 15 | Schwab S&P 500 Index Fund | 3,911,905 | $428M | Jan 2026 |
| 16 | Fidelity Total Market Index Fund | 3,251,382 | $378M | Feb 2026 |
| 17 | State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 3,655,390 | $375M | Mar 2026 |
| 18 | iShares MSCI USA Quality Factor ETF | 3,093,680 | $338M | Jan 2026 |
| 19 | iShares Core Dividend Growth ETF | 2,807,061 | $307M | Jan 2026 |
| 20 | GMO Quality Fund | 2,618,724 | $305M | Feb 2026 |
Valuation
Market Cap
$153.94B
Enterprise Value
$156.34B
P/E (TTM)
23.77x
Forward P/E
16.12x
PEG Ratio
-0.65x
P/B
2.93x
P/S
3.48x
P/FCF
20.88x
EV/EBITDA
13.53x
Shares Out
1.75B
Financials (TTM)
Revenue
$44.33B
Net Income
$6.52B
EBITDA
$11.55B
Free Cash Flow
$7.39B
Op Cash Flow
$9.57B
EPS Basic
$3.74
EPS Diluted
$3.72
EPS Forward
$5.48
Gross Margin
55.5%
Op Margin
18.2%
Net Margin
14.7%
Balance Sheet
Total Assets
$86.71B
Total Liab.
$33.94B
Total Equity
$52.77B
Cash
$8.94B
LT Debt
$10.83B
Book Value/Sh
$30.21
Debt/Equity
0.29x
Current Ratio
1.58
Quick Ratio
1.18
Returns & Growth
ROE
12.1%
ROA
5.7%
ROIC
8.4%
Rev Growth YoY
+5.7%
EPS Growth YoY
-51.2%
Price Returns
2W
+0.8%
1M
-5.7%
3M
-26.4%
6M
-33.6%
12M
-35.9%
Technicals
52W High
$139.06
52W Low
$81.97
50d MA
$90.43
200d MA
$113.85
RSI (14)
58.20
ATR (14)
$2.06
Beta
0.78
Avg Volume
13.3M
Dividends
Div Rate
$2.36
Div Yield
2.6%
Frequency
4
Ex-Div Date
Apr 15, 2026
Analyst Price Targets
Consensus
$128.71
High
$152.00
Low
$92.00
Median
$125.00
Data updated apr 24, 2026 10:18am
· Source: financialmodelingprep.com